News headlines about Lantheus (NASDAQ:LNTH) have been trending positive recently, Accern reports. The research group scores the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Lantheus earned a media sentiment score of 0.31 on Accern’s scale. Accern also assigned media coverage about the medical equipment provider an impact score of 46.2792590697932 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
LNTH has been the subject of several recent analyst reports. Wells Fargo & Co raised shares of Lantheus from a “market perform” rating to an “outperform” rating in a research note on Thursday, November 2nd. Credit Suisse Group lifted their target price on shares of Lantheus from $19.00 to $23.00 and gave the stock a “neutral” rating in a research note on Friday, November 3rd. Jefferies Group lifted their target price on shares of Lantheus from $22.00 to $27.00 and gave the stock a “buy” rating in a research note on Friday, November 3rd. Zacks Investment Research raised shares of Lantheus from a “hold” rating to a “strong-buy” rating and set a $26.00 target price for the company in a research note on Tuesday, November 7th. Finally, ValuEngine cut shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $24.75.
Shares of Lantheus (NASDAQ LNTH) opened at $19.80 on Monday. Lantheus has a 12 month low of $10.65 and a 12 month high of $24.45. The stock has a market cap of $742.62, a price-to-earnings ratio of 24.44, a PEG ratio of 1.28 and a beta of 0.95. The company has a current ratio of 2.96, a quick ratio of 2.46 and a debt-to-equity ratio of -3.41.
COPYRIGHT VIOLATION NOTICE: “Favorable Press Coverage Somewhat Unlikely to Affect Lantheus (LNTH) Share Price” was originally published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://www.tickerreport.com/banking-finance/3223420/favorable-press-coverage-somewhat-unlikely-to-affect-lantheus-lnth-share-price.html.
Lantheus Company Profile
Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.